Asarfi Hospital Q2 FY27: Consol PAT Up 45% YoY to ₹6.09 Cr, EBITDA Margin Hits 23.4%
PAT +45.16% YoY · revenue +18.15% · margins expanding
₹53.04 Cr
+18.15% YoY
₹6.09 Cr
+45.16% YoY
11.34%
+2.5pp YoY
₹3.1
Asarfi Hospital's consolidated PAT rose 45.2% YoY to ₹6.09 Cr in Q2 FY27 (quarter ended 30 Sep 2026), outpacing an 18.1% YoY rise in revenue from operations to ₹53.04 Cr, as net margin (PAT/total income) expanded to 11.34% from 9.19% a year ago. QoQ, PAT was up 42.8% and revenue 11.6% versus Q1 FY27 — a hospital operator isn't materially seasonal, so this sequential strength reflects genuine ramp rather than a calendar artifact. Neither the current quarter nor any comparable period carries an exceptional or extraordinary item, so the growth is operational, not one-off driven.
Q2 FY-2027 vs prior quarters
The margin expansion shows at the operating level too: EBITDA margin (PBT + depreciation + finance cost, over total income) came in at roughly 23.4% this quarter versus ~21.1% a year ago and ~20.8% last quarter — already inside the 22-25% band management guided for FY27 (up from ~20% in FY26) on its May 2026 concall. Against that same call's FY27 revenue target of ₹260 Cr, H1 FY27 consolidated revenue of ₹100.57 Cr is only ~38.7% of the full-year goal, meaning H2 would need to come in near ₹159 Cr — about 58% above H1 — to hit it; that back-loaded requirement makes the revenue-guidance call 'unknown' rather than on-track, resting on the planned ramp of bed capacity (the cancer hospital's expansion from 65 to 150 beds under Vision 2028) actually landing in H2. No consensus estimates for this quarter turned up in a web search — Asarfi carries no active brokerage coverage — so vsStreet is unknown. No standalone management press release accompanied this filing beyond the standard board-outcome letter to BSE, so there is no additional management commentary to reconcile against the print.
The stock went into the print at ₹182, down 0.5% over the past month of trading.
Asarfi Hospital provided an optimistic outlook, targeting revenue of INR260 crores for FY27, with a mix of organic and inorganic growth, including potential acquisitions. The company aims to significantly scale its bed capacity to over 500 beds by Vision 2028, with aggressive expansion plans for the cancer hospital fro
Standalone and consolidated numbers are nearly identical (standalone PAT ₹6.14 Cr vs consolidated ₹6.09 Cr), confirming the Asarfi Educational Foundation subsidiary's contribution is immaterial to the group result. The quarter's other disclosed events — the FY26 annual report/AGM filing, BSE/NSE migration approval, and cost-auditor appointment — are governance housekeeping rather than operational drivers and don't bear on this print.
W1
H2 FY27 revenue needs to reach ~₹159 Cr (vs ₹100.57 Cr in H1) to hit management's ₹260 Cr FY27 target
W2
Cancer hospital bed expansion from 65 to 150 beds (Vision 2028) — progress check in coming quarters as the key capacity driver
W3
EBITDA margin sustaining the 22-25% band (23.4% this quarter) as new bed capacity comes online, since fresh capacity often dilutes margins initially